VIENNA, Va., March 19 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM) announces that Dr. Eyal Talor of CEL-SCI has been invited to
speak at the First International Congress of the International Academy of
Oral Oncology in Amsterdam, May 17-20, 2007.
Dr. Talor will present data from CEL-SCI's last Phase II clinical study
that was conducted in advanced primary head and neck cancer patients with
the Company's cancer product Multikine(R). These data established a
statistically meaningful increase in long term survival of the study
subjects treated with Multikine. Dr. Talor will also discuss a number of
other critical findings from the study.
Based on the results of this last Phase II clinical study, CEL-SCI has
designed and will undertake a Phase III study with Multikine using the same
treatment regimen, as was used in this Phase II study. The Company has
already received the go-ahead from both the U.S. FDA and the Canadian
regulators to proceed with a Phase III clinical trial with Multikine.
Multikine is being developed as first-line treatment of patients with
advanced primary head and neck cancer.
Geert Kersten, Chief Executive Officer of CEL-SCI said, "Multikine is
being developed in a different manner than most cancer products. It is
being developed as a first-line therapy, not as a late stage treatment and
it is given to cancer patients prior to surgery, not afterwards. The goal
of Multikine treatment is not tumor reduction, but the elimination of the
tumor micro-metastases that are the main cause of recurrence in this
disease. We are pleased to see that the cancer research and drug
development communities are becoming increasingly interested in our
promising results."
Multikine is a patented immunotherapeutic agent consisting of a defined
mixture of naturally occurring cytokines, including interleukins,
interferons, chemokines and colony-stimulating factors.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
